CClinicalTrials.gg
Sign In
RecruitingNCT06377527Updated Jul 22, 2026

Establishing a Tumor Registry of Patients With Mesonephric-like Adenocarcinoma (MLA)

An observational study in Mesonephric-like Adenocarcinoma, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by M.D. Anderson Cancer Center · Observational

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 2 months later.
Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
2,000
Ages
18 Years and older
Sex
All
01

Study summary

To develop a database of medical information about patients with MLA in an effort to increase our understanding of the characteristics of MLA, which is the rarest form of endometrial carcinoma.

Read the detailed description

Primary Objectives

1. To collect data on participants characteristics, disease characterization, pathology and molecular data, treatment, and outcomes for participants with gynecologic mesonephric-like adenocarcinoma (MLA).

Secondary Objectives

  1. To organize clinical information to support multifaceted queries of participant characteristics, treatment, and disease outcome data and to facilitate correlation of these characteristics with participant outcome.
  2. To have a single data repository kept on a secure platform that will integrate clinical information and research findings and serve as an archive for future research.
02

Conditions studied

  • Mesonephric-like Adenocarcinoma
03

In context

Lead sponsor

M.D. Anderson Cancer Center is the lead sponsor of 2,999 studies on the registry; 581 are open to participants now.

Of its 599 completed or terminated interventional studies of FDA-regulated products, 402 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

MD Anderson

Inclusion criteria

  1. Adult patients over the age of 18.
  2. Patients with a diagnosis of gynecologic mesonephric-like adenocarcinoma (MLA), mesonephric adenocarcinoma (MA), mesonephric carcinosarcoma, or mesonephric-like carcinosarcomas.
  3. For patients who provide consent, they must speak and/or read English or Spanish.

Exclusion criteria

Exclusion Criteria:

  1. Patients with other subtypes of EACs.
  2. Patients who are considered cognitively impaired. Assessment will be obtained based on their need of a Legally Authorized Representative.
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
2,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Mesonephric-like Adenocarcinoma (MLA)

    Particpants who agree to take part in this research, information such as your demographics (including your name, date of birth, race, etc.), medical history, surgical history, family history, social history, cancer diagnosis, primary treatment, and follow up will be collected. Participants also have the option to agree to the use of your previously collected tumor tissue samples for future research to better understand MLA.

06

What researchers measure

Primary outcomes

  1. Tumor Registry

    The goal of this data collection study is to develop a database (i.e. a registry/repository) of medical information about patients with MLA in an effort to increase our understanding of the characteristics of MLA, which is the rarest form of endometrial carcinoma.

    Time frame: Through study completion; an average of 1 year

07

Study locations

1 of 1 sites recruiting
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
    • Jeffrey How, MD · Contact
    • Jeffrey How, MD · Principal investigator
    Recruiting
08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06377527
Lead sponsor
M.D. Anderson Cancer Center
Responsible party
Sponsor
First posted
Apr 22, 2024
Start date
Jul 10, 2024
Primary completion
Dec 28, 2035 (estimated)
Completion
Dec 28, 2037 (estimated)
Last update
Jul 22, 2026

Study contacts

Jeffrey How, MD
Contact
askmdanderson@mdanderson.org
877-632-6789
Jeffrey How, MD
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

M.D. Anderson Cancer Center

Start the discussion